Leaderboards/PD-1/PD-L1

PD-1/PD-L1

Last updated May 19, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Zachary Sethna
Memorial Sloan Kettering Cancer Center
666 cit.
2
Jonathan Spicer
Unknown
651 cit.
3
Rongxuan Zhu
Zhejiang Cancer Hospital
606 cit.
4
Peter R. Galle
Johannes Gutenberg University Mainz
438 cit.
5
Ferdinandos Skoulidis
The University of Texas MD Anderson Cancer Center
435 cit.
6
Aram Lyu
University of California, San Francisco
384 cit.
7
Huan Tong
Sichuan University
354 cit.
8
Ying Cheng
Jilin Province Tumor Hospital
348 cit.
9
Anwen Xiong
Tongji University
348 cit.
10
Matthew D. Galsky
Icahn School of Medicine at Mount Sinai
285 cit.

Rising Stars Papers

1
RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer
Nature|2025
221 cit.
2
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet|2024
216 cit.
3
ACSS2 acts as a lactyl-CoA synthetase and couples KAT2A to function as a lactyltransferase for histone lactylation and tumor immune evasion
Cell Metabolism|2024
201 cit.
4
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
Journal of Clinical Oncology|2024
145 cit.
5
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Nature|2024
144 cit.
6
Evolution of myeloid-mediated immunotherapy resistance in prostate cancer
Nature|2024
127 cit.
7
Dual impacts of serine/glycine-free diet in enhancing antitumor immunity and promoting evasion via PD-L1 lactylation
Cell Metabolism|2024
117 cit.
8
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial
Nature Medicine|2024
115 cit.
9
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
The Lancet|2025
115 cit.
10
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274
Journal of Clinical Oncology|2024
94 cit.

Rising Stars Reagents

Coming soon

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Sun Young Rha
Yonsei University
446 cit.
2
Zhiming Huang
Unknown
340 cit.
3
Bo Xiang
Unknown
294 cit.
4
Rui‐Hua Xu
ShenZhen People’s Hospital
222 cit.
5
Martin Reck
The University of Texas MD Anderson Cancer Center
215 cit.
6
Donald M. O’Rourke
University of Pennsylvania
203 cit.
7
Hui‐Kuan Lin
Atrium Health Wake Forest Baptist
197 cit.
8
Lihua Liu
Hebei Medical University
190 cit.
9
Guangshuai Jia
Xuzhou Medical College
178 cit.
10
Mark M. Awad
Dana-Farber Cancer Institute
176 cit.

Emerging Leaders Papers

1
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
The Lancet|2023
446 cit.
2
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
JAMA|2023
340 cit.
3
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
Journal of Clinical Oncology|2023
304 cit.
4
Regulatory mechanisms of PD-1/PD-L1 in cancers
Molecular Cancer|2024
587 cit.
5
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma
JAMA|2023
222 cit.
6
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
Journal of Clinical Oncology|2023
218 cit.
7
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
New England Journal of Medicine|2023
644 cit.
8
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial
Nature Cancer|2024
162 cit.
9
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
The Lancet Oncology|2023
598 cit.
10
NSUN2 is a glucose sensor suppressing cGAS/STING to maintain tumorigenesis and immunotherapy resistance
Cell Metabolism|2023
197 cit.

Emerging Leaders Reagents

Coming soon

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
19.8k cit.
2
Edward B. Garon
University of California, Los Angeles
19.5k cit.
3
Thomas Powles
Queen Mary University of London
16.3k cit.
4
F. Stephen Hodi
Unknown
15.7k cit.
5
David R. Gandara
University of California, Davis
14.3k cit.
6
Mario Sznol
Yale Cancer Center
12.6k cit.
7
Rafi Ahmed
Emory University
11.8k cit.
8
Terrill K. McClanahan
Merck & Co., Inc., Rahway, NJ, USA (United States)
11.5k cit.
9
Thomas F. Gajewski
University of Chicago
11.2k cit.
10
Robert Dreicer
University of Virginia
11.1k cit.

All-Time Leaders Papers

1
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Nature|2014
6.6k cit.
2
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
The Lancet|2015
6.5k cit.
3
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Nature|2018
5.4k cit.
4
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Nature|2014
5.2k cit.
5
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
The Lancet|2016
4.8k cit.
6
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
New England Journal of Medicine|2012
12.6k cit.
7
Restoring function in exhausted CD8 T cells during chronic viral infection
Nature|2005
3.9k cit.
8
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Journal of Clinical Investigation|2017
3.8k cit.
9
Commensal <i>Bifidobacterium</i> promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Science|2015
3.7k cit.
10
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
The Lancet|2016
3.7k cit.

All-Time Leaders Reagents

Coming soon

Indexing PD-1/PD-L1 Reagents

Citation data for reagents in this field is currently compiling.